AGB101 Market

“AGB101 Market Size, Forecast, and Emerging Insight − 2032” report provides comprehensive insights about AGB101 for Alzheimer’s disease in Japan. A detailed picture of the AGB101 for Alzheimer’s disease in Japan for the study period 2019 –2032 is provided in this report along with a detailed description of the AGB101 for Alzheimer’s disease. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the AGB101 market forecast analysis for Alzheimer’s disease in Japan, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in Alzheimer’s disease.

Drug Summary

AGB101 is a proprietary extended-release formulation of levetiracetam, an FDA-approved anti-epileptic. AGB101 is being evaluated for MCI due to Alzheimer’s disease as a once-daily dose given to patients at approximately 1/12th of the dose most commonly prescribed for epilepsy. Levetiracetam treats epilepsy by decreasing abnormal activity in the brain, specifically the hippocampus. The hippocampus plays a crucial role in forming memories and is also where people with MCI express abnormal activity (though at much lower levels). In animal models, tiny doses of levetiracetam have lowered activity levels and improved memory. 

AGB101 is currently being studied in patients with mild cognitive impairment due to Alzheimer’s disease. Hope4MCI (Phase II/III trial) data acquisition was completed in November and the database lock and unblinding occurred in Q4 2022, with data analysis in Q1 2023.

The company is currently conducting a Phase III study, to evaluate the efficacy of AGB101 on slowing cognitive and functional impairment as measured by changes in the Clinical CDR-SB score as compared with placebo in participants with mild cognitive impairment due to Alzheimer's disease.

In addition to Alzheimer’s disease, AGB101 is also being developed for Parkinson’s disease psychosis, and a novel late-stage discovery program with GABAA α5 PAM is being evaluated for a spectrum of conditions, including MCI due to Alzheimer’s disease.

Gain a deeper understanding of the Market with DelveInsight’s detailed report @ Alzheimer’s Disease Treatment Market Size

Scope of the Report 

The report provides insights into:

• A comprehensive product overview including the AGB101 description, mechanism of action, dosage and administration, research and development activities in Alzheimer’s disease.
• Elaborated details on AGB101 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the AGB101 research and development activities in Alzheimer’s disease across Japan.
• The report also covers the patents information with expiry timeline around AGB101.
• The report contains forecasted sales of AGB101 for Alzheimer’s disease till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Alzheimer’s disease.
• The report also features the SWOT analysis with analyst views for AGB101 in Alzheimer’s disease.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Unlock comprehensive insights! Click Here to Purchase the Full Epidemiology Report @ Alzheimer’s Disease Prevalence

AGB101 Analytical Perspective by DelveInsight

• In-depth AGB101 Market Assessment

This report provides a detailed market assessment of AGB101 for Alzheimer’s disease in Japan. This segment of the report provides forecasted sales data from 2031 to 2032.

• AGB101 Clinical Assessment

The report provides the clinical trials information of AGB101 for Alzheimer’s disease covering trial interventions, trial conditions, trial status, start and completion dates.

Take Your Research to the Next Level! Click Here to Get Access to the Full Pipeline Report @ Alzheimer’s Disease Treatment Drugs

Report Highlights  

• In the coming years, the market scenario for Alzheimer’s disease is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.   
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence AGB101 dominance.
• Other emerging products for Alzheimer’s disease are expected to give tough market competition to AGB101 and launch of late-stage emerging therapies in the near future will significantly impact the market. 
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of AGB101 in Alzheimer’s disease.
• Our in-depth analysis of the forecasted sales data of AGB101 from 2031 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the AGB101 in Alzheimer’s disease. 

Key Questions

• What is the product type, route of administration and mechanism of action of AGB101?
• What is the clinical trial status of the study related to AGB101 in Alzheimer’s disease and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the AGB101 development?
• What are the key designations that have been granted to AGB101 for Alzheimer’s disease?
• What is the forecasted market scenario of AGB101 for Alzheimer’s disease?
• What are the forecasted sales of AGB101 in Japan?  
• What are the other emerging products available and how are these giving competition to AGB101 for Alzheimer’s disease?
• Which are the late-stage emerging therapies under development for the treatment of Alzheimer’s disease?